Seres Therapeutics Inc (NASDAQ:MCRB) Expected to Announce Quarterly Sales of $6.82 Million

Wall Street analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post $6.82 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Seres Therapeutics’ earnings. The highest sales estimate is $9.26 million and the lowest is $3.00 million. Seres Therapeutics reported sales of $10.63 million during the same quarter last year, which indicates a negative year over year growth rate of 35.8%. The company is scheduled to announce its next quarterly earnings results on Wednesday, March 4th.

On average, analysts expect that Seres Therapeutics will report full year sales of $34.21 million for the current financial year, with estimates ranging from $29.88 million to $36.14 million. For the next fiscal year, analysts forecast that the company will post sales of $32.51 million, with estimates ranging from $18.70 million to $43.83 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. The firm had revenue of $7.03 million for the quarter, compared to analysts’ expectations of $6.69 million.

MCRB has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. BidaskClub upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 7th. Cowen restated a “buy” rating on shares of Seres Therapeutics in a research note on Monday, November 4th. ValuEngine upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Chardan Capital restated a “buy” rating on shares of Seres Therapeutics in a research note on Thursday, September 19th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $7.75.

MCRB stock traded up $0.15 during mid-day trading on Wednesday, reaching $3.87. 192,900 shares of the stock traded hands, compared to its average volume of 188,710. The stock’s fifty day moving average is $3.49 and its 200-day moving average is $3.51. The company has a market cap of $258.28 million, a P/E ratio of -1.59 and a beta of 1.78. Seres Therapeutics has a 52-week low of $2.02 and a 52-week high of $8.82.

Several institutional investors have recently made changes to their positions in MCRB. Tower Research Capital LLC TRC grew its stake in shares of Seres Therapeutics by 3,656.7% in the second quarter. Tower Research Capital LLC TRC now owns 8,678 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 8,447 shares during the last quarter. Aries Wealth Management bought a new position in Seres Therapeutics in the third quarter worth $31,000. SG Americas Securities LLC bought a new position in Seres Therapeutics in the second quarter worth $34,000. Parametric Portfolio Associates LLC bought a new position in Seres Therapeutics in the second quarter worth $42,000. Finally, A.R.T. Advisors LLC bought a new position in Seres Therapeutics in the second quarter worth $64,000. Institutional investors and hedge funds own 95.89% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

See Also: Cash Asset Ratio

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.